I'm of the belief that most of the longs are largely satisfied with the positions they've built. The Nature article, while clearly positive, was really only being seen by people already interested in NWBO, most of whom are already investors. Volume wasn't high and the MM's were able to take control after the initial runup today. This won't remain the case when we get word of an approval for DCVax-L.
I doubt if 1% of the investing public have ever heard of NWBO. I suspect that with news of DCVax-L approval in the UK no less than 25%, and perhaps 50% or more will have at least heard of NWBO. Hearing about it doesn't make them buyers, but if even a small percentage of those who hear about it choose to invest, the total number of investors go up by a substantial multiple.
If we get the sort of headlines that creates buying on emotion, we'll get investors who want in, and they don't care about the price, they want their 100, 1000, or 10,000 shares and if it's costing them $5, $10 or more a share. It won't matter to them that over a billion shares are outstanding and the price they're paying is saying the company warrants a market cap that's approaching or is over $10 billion.
Personally I believe that in time NWBO should be worth many tens of billions, even hundreds of billions and more, but perhaps just UK approval along is premature for a $10 billion plus market cap being sustained. In time the investor who pays $10 or more will do just fine by holding, but I suspect many of us will be selling some shares, and looking to buy back substantially more shares when the stock retrenches.
As for volume, once we get UK approval, I would expect 10 million and greater days will become common, at least for awhile. I don't know that we won't get over 100 million for a few days. Life should really be interesting at that time.
Gary
Bullish
